Illumina Inc. ($ILMN) Stock Forecast: Down 5.2% Today

What is Illumina Inc.?

Illumina, Inc. (ILMN) operates in the Pharmaceuticals & Biotechnology sector, specializing in genetic sequencing and array-based technologies. The company has a track record of solid financial performance and operational efficiency.

Why is Illumina Inc. going down?

ILMN stock is down 5.2% on Apr 29, 2026 18:01

• The downward trend in Illumina's stock today could be due to profit-taking following a recent increase in value.
• Insider selling by Universal Beteiligungs und Servicegesellschaft mbH may have influenced market sentiment, leading to a decrease in the stock price.
• Despite strong financial metrics and outperforming competitors on Friday, consecutive days of losses and broader market trends may have contributed to the downward movement.
• Competition in the Human Microbiome Sequencing Technology market, where Illumina is a prominent player, could also be impacting investor sentiment and trading patterns.

ILMN Price Chart

ILMN Technical Analysis

ILMN News

Illumina, Inc. Experiences Revision in Its Stock Evaluation Amid Strong Financial Metrics

Illumina, Inc. has revised its stock valuation, demonstrating strong financial performance with a P/E ratio of 36, a PEG ratio of 0.64, and a robust ROCE of 28.32%. The company's one-year return of 64.77% significantly surpassed the S&P 500's performance, highlighting its competitive standing in the Pharmaceuticals & Biotechnology sector despite recent year-to-date fluctuations. These metrics indicate a favorable growth outlook and strong operational efficiency compared to its peers.

https://www.marketsmojo.com/news/stocks-in-action/illuminas-valuation-grade-upgraded-from-fair-to-very-attractive-amid-strong-performance-3964903

Illumina Inc. stock outperforms competitors on strong trading day

Illumina Inc. (ILMN) saw its stock advance by 1.95% to $127.88 on Friday, outperforming the broader market during a mixed trading session. This rise ended a four-day losing streak for the company. The S&P 500 Index rose, while the Dow Jones Industrial Average experienced a slight fall.

https://www.marketwatch.com/data-news/illumina-inc-stock-outperforms-competitors-on-strong-trading-day-c31fc2f5-01c0acb3fe98

Universal Beteiligungs und Servicegesellschaft mbH Sells 15,739 Shares of Illumina, Inc. $ILMN

Universal Beteiligungs und Servicegesellschaft mbH has reduced its stake in Illumina, Inc. (NASDAQ:ILMN) by selling 15,739 shares, leaving them with 192,296 shares valued at $25.32 million. This move comes as Illumina reported stronger-than-expected quarterly earnings and revenue, providing FY2026 guidance that analysts anticipate. Despite a consensus "Hold" rating and institutional ownership of nearly 90%, the stock experienced a recent dip of approximately 3.9%, alongside ongoing insider selling.

https://www.marketbeat.com/instant-alerts/filing-universal-beteiligungs-und-servicegesellschaft-mbh-sells-15739-shares-of-illumina-inc-ilmn-2026-04-24/

Human Microbiome Sequencing Technology Market Competitive Analysis to 2034 | Thermo Fisher Scientific Inc., QIAGEN N.V., Microbiome Insights Inc., Leucine Rich Bio Pvt. Ltd., Illumina, Inc etc.

The global Human Microbiome Sequencing Technology market is projected to grow from US$ 2.19 billion in 2025 to US$ 4.92 billion by 2034, driven by increasing awareness of the microbiome's role in health, rising chronic diseases, and advancements in sequencing technologies like Next Generation and Third Generation Sequencing. North America currently leads the market, but Asia Pacific is expected to see the fastest growth. Key players include Thermo Fisher Scientific Inc., QIAGEN N.V., and Illumina, Inc., who are investing in innovation and strategic partnerships.

https://www.openpr.com/news/4487512/human-microbiome-sequencing-technology-market-competitive

Illumina Inc. stock underperforms Thursday when compared to competitors

Illumina Inc. (ILMN) shares fell 3.88% to $125.44 on Thursday, underperforming the broader stock market, which saw the S&P 500 Index (SPX) and Dow Jones Industrial Average (DJIA) also decline. This marks the fourth consecutive day of losses for the stock.

https://www.marketwatch.com/data-news/illumina-inc-stock-underperforms-thursday-when-compared-to-competitors-5d7b5756-99c7b764dcbd?mod=mw_quote_news

Trending Today

IDEX Corporation ($IEX) Stock Forecast: Up 5.8% Today

Chegg Inc. ($CHGG) Stock Forecast: Up 7.5% Today

Beyond Meat Inc. ($BYND) Stock Forecast: Down 5.8% Today

T-Mobile US Inc. ($TMUS) Stock Forecast: Up 6.8% Today

Crude Oil ($CRUDE) Commodity Forecast: Up 7.5% Today

Unum Group ($UNM) Stock Forecast: Up 5.3% Today

Humana Inc. ($HUM) Stock Forecast: Up 5.0% Today

BlackBerry Limited ($BB) Stock Forecast: Up 5.5% Today

Akamai Technologies Inc. ($AKAM) Stock Forecast: Up 5.0% Today

Amylyx Pharmaceuticals ($AMLX) Stock Forecast: Down 5.1% Today

Illumina Inc. Price History

20.00.2026 - ILMN Stock was up 5.1%

• The bullish movement in Illumina's stock could be attributed to the company's partnership with pharma giants like AstraZeneca, Merck, and Eli Lilly to launch the Billion Cell Atlas initiative. This ambitious project aims to map genetic perturbations in five billion human cells, providing valuable insights for drug discovery and precision medicine.
• The collaboration with major pharmaceutical companies highlights Illumina's commitment to advancing genomic research and its potential to revolutionize the field of AI-driven drug discovery.
• The emphasis on creating a comprehensive genetic dataset to accelerate drug discovery and improve target validation likely resonated positively with investors, driving the bullish market movement in Illumina's stock today.

20.00.2026 - ILMN Stock was up 5.2%

• The bullish movement in Illumina's stock today is due to Medicare's decision to cover the TruSight™ Oncology Comprehensive test, enabling a clear reimbursement pathway and broadening access to precision oncology. This development is expected to significantly boost Illumina's revenue and enhance investor confidence in the company's clinical focus.
• Illumina's collaboration with major pharmaceutical companies like AstraZeneca, Merck, and Eli Lilly on the Billion Cell Atlas initiative is a testament to its dedication to advancing drug discovery and precision medicine by mapping disease biology at an unprecedented scale. This partnership underscores Illumina's leading position in genomic research and innovation, strengthening its market presence and growth potential.
• The company's integrated genomic workflow solutions for genetic disease research, which prioritize high-quality genomic data generation and interpretation, also contribute to its positive market sentiment. Illumina's holistic approach to genetic research and emphasis on scalable informatics are resonating well with investors, fueling optimism about the company's future prospects in the genomics industry.

21.00.2026 - ILMN Stock was up 5.1%

• Illumina's stock surged today following the news of securing CMS reimbursement for its TruSight Oncology Comprehensive test at $2,989.55 per test, effective January 1, 2026. This reimbursement is expected to drive adoption of the test, boosting Illumina's market share and revenue.
• The partnership with pharma giants like AstraZeneca, Merck, and Eli Lilly to map disease biology at an unprecedented scale through the Billion Cell Atlas initiative also contributed to the bullish movement. This collaboration enhances Illumina's position in the precision medicine field and strengthens its role in accelerating drug discovery processes.
• Analysts' positive outlook on Illumina's earnings growth and target price increases from firms like TD Cowen and Guggenheim further fueled investor optimism, driving the stock higher.
• Illumina's focus on offering integrated genomic workflow solutions for genetic disease research and emphasizing scalable informatics and high-quality genomic data generation also added to the positive market sentiment, showcasing the company's commitment to innovation and advancement in the genomics industry.

06.01.2026 - ILMN Stock was down 12.3%

• Despite strong Q4 2025 earnings that surpassed expectations, Illumina's stock saw a notable decline following a cautious 2026 revenue outlook.
• Investor response suggests disappointment with the company's conservative forecast for the upcoming period, despite its previous strong performance.
• Illumina's strategic focus on core sequencing, multiomics scaling, and data/software expansion is contributing to its momentum. However, concerns around the subdued 2026 revenue guidance seemed to overshadow these accomplishments for investors.
• While the company remains optimistic about the growing adoption of sequencing-based diagnostic tests and the NovaSeq X instrument in clinical settings, these positive prospects were unable to offset worries about future growth potential, resulting in a bearish trend for the stock.

06.01.2026 - ILMN Stock was down 9.6%

• Despite surpassing Q4 earnings forecasts, Illumina's stock trended bearishly due to its conservative 2026 revenue guidance, disappointing investors who were anticipating a more aggressive outlook.
• The market's response suggests that investors are evaluating Illumina's robust operational performance in Q4 against its unchanging annual revenue for 2025, which paralleled the previous year.
• Although Illumina offered a positive forecast for 2026, anticipating revenue growth of 4-6% and adjusted EPS of $5.05-$5.20, the stock's decline indicates that investors possibly anticipated more ambitious future projections.
• The contrast between the company's solid financial performance and the market's reaction underscores the significance of managing investor expectations and articulating a compelling growth narrative for forthcoming results.

29.03.2026 - ILMN Stock was down 5.2%

• The downward trend in Illumina's stock today could be due to profit-taking following a recent increase in value.
• Insider selling by Universal Beteiligungs und Servicegesellschaft mbH may have influenced market sentiment, leading to a decrease in the stock price.
• Despite strong financial metrics and outperforming competitors on Friday, consecutive days of losses and broader market trends may have contributed to the downward movement.
• Competition in the Human Microbiome Sequencing Technology market, where Illumina is a prominent player, could also be impacting investor sentiment and trading patterns.

06.00.2026 - ILMN Stock was up 5.3%

• In spite of regulatory challenges and cautious sentiment from investors, Illumina demonstrated significant bullish momentum today.
• While receiving "hold" ratings from Wall Street Zen and Zacks Research, the company surpassed Q3 earnings projections and offered optimistic FY2025 guidance, resonating well with investors.
• The positive market response can be linked to hopeful investor sentiment regarding Illumina's anticipated recovery, supported by its strategic capital allocation and increasing demand for sequencing.
• Illumina's efforts to adapt to the AI era and consolidate its place in the genomics sector have instilled a sense of cautious optimism among investors and insiders about the company's future trajectory.

27.02.2026 - ILMN Stock was down 5.9%

• Illumina's stock experienced a bearish movement due to regulatory scrutiny over its past Grail acquisition and a slowdown in the biotech sector, leading to softening demand in genomic sequencing and increased competition.
• The short-term corrective bearish wave, negative pressure from technical indicators like the 50-day SMA and overbought Stochastic indicators, contributed to the decline in Illumina's stock price.
• Despite positive news such as Nordea Investment Management AB significantly increasing its stake in Illumina and the company reporting strong Q4 earnings, the mixed analyst sentiment and challenges in the industry have put pressure on the stock.
• The launch of Illumina's TruPath™ Genome tool aims to provide deeper insights into complex genomic regions, showcasing the company's commitment to advancing genomic research amidst market challenges.

24.01.2026 - ILMN Stock was up 5.6%

• The positive outlook on the genomics market and the company's advancements in technology and informatics are driving the bullish movement in Illumina's stock today.
• Illumina's pivotal role in genomic projects like the UK Biobank, as highlighted in an interview with Rami Mehio, underscores their expertise and contributions to the field.
• Despite recent insider selling by SVP Patricia Leckman, investors remain confident due to the company's aggressive share buybacks and robust financial health score.
• Anticipated growth in the global genomics market and Illumina's potential revenue expansion through acquisitions like SomaLogic are likely factors boosting investor optimism and contributing to the current bullish trend.

23.03.2026 - ILMN Stock was down 5.3%

• Illumina Inc. (ILMN) saw a 1.34% increase in its stock value, falling behind its industry peers, possibly indicating weaknesses in its competitive position.
• The stock's fifth consecutive day of gains may have prompted investors to take profits, leading to downward pressure on its price.
• Despite positive performances in the market with the S&P 500 and Dow Jones Industrial Average both rising, the decline in Illumina's stock could be attributed to internal factors rather than broader market trends.

09.11.2025 - ILMN Stock was up 3.2%

• The bullish movement of Illumina is linked to its active participation and partnerships at the 2025 CIIE, showcasing its commitment to the Chinese market and highlighting potential growth opportunities.
• The recent share price rebound and positive gains over 30 and 90 days indicate investor confidence in Illumina's future prospects, despite some fluctuations over the past year.
• Analysts' mixed views on Illumina's valuation suggest ongoing debates regarding the stock's pricing, with considerations around future growth expectations and cash flow trajectory influencing investor sentiment.

09.00.2026 - ILMN Stock was down 5.1%

• Today's bearish movement in Illumina's stock value might stem from concerns over regulatory challenges and changes in investor sentiment.
• The recent introduction of Illumina Connected Multiomics, a robust software platform for simplifying multiomic analysis in precision medicine, aimed to drive faster discovery. However, it might not have sufficiently addressed worries regarding the company's divestment plans and market demand uncertainties.
• Despite surpassing Q3 earnings expectations and offering promising FY2025 guidance, Illumina saw a downgrade to a "hold" rating by Wall Street Zen. This action could have influenced the stock's decline as investors rethought their positions.
• The anticipated rapid growth of the DNA Test Kits Market suggests a favorable industry forecast. Nevertheless, Illumina's performance might have been eclipsed by broader market dynamics and company-specific concerns.